Comparison of the results on phenotypic and genotypic resistance to antituberculosis drugs, Mexico, 2010–2017
| Phenotypic results (n=112)# | Genotypic results (n=57)# | κ (95% CI) | |
| Fluoroquinolone resistant | 26/111 (23.4%) | 12/57 (21.1%) | 0.894 (0.751–1.000) |
| Ofloxacin resistant | 26/111 (23.4%) | ||
| Moxifloxacin resistant | 8/49 (16.3%) | ||
| Injectable resistant | 13/111 (11.7%) | 1/57 (1.8%) | 0.226 (-0.145–0.597) |
| Amikacin resistant | 9/111 (8.1%) | ||
| Kanamycin resistant | 10/92 (10.9%) | ||
| Capreomycin resistant | 6/50 (12.0%) | ||
| Ethambutol resistant | 38/112 (33.9%) | 19/57 (33.3%) | 0.763 (0.585–0.942) |
| Isoniazid resistant | 97/112 (86.6%) | 31/57 (54.4%) | 0.597 (0.402–0.793) |
| katG and inhA mutations | 1/57 (1.8%) | ||
| katG mutation only | 18/57 (31.6%) | ||
| inhA mutation only | 14/57 (24.6%) | ||
| Pyrazinamide resistant | 46/110 (41.8%) | ||
| Eligible for the shorter regimen | |||
| Criterion 1 | 80 (71.4%) | ||
| Criterion 2 | 56 (50.0%) | ||
| Criterion 3 | 50 (44.6%) |
Criterion 1: eligible if no resistance to fluoroquinolones and injectables, and no katG or inhA mutations; criterion 2: eligible as per criterion 1 plus no resistance to ethambutol; criterion 3: eligible as per criterion 2 but no katG mutation (see text for details). #: the denominators vary as not necessarily all 112 strains underwent testing for all the drugs due to lack of reagents.